References
Charilaou P, Devani K, Petrosyan R, et al. Inpatient mortality benefit with transjugular intrahepatic portosystemic shunt for hospitalized hepatorenal syndrome patients. Dig Dis Sci. 2020;. https://doi.org/10.1007/s10620-020-06136-2.
Testino G, Ferro C, Sumberaz A, et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology. 2003;50:1753–1755. PMID:14696397.
Testino G, Ferro C. Type-1 hepatorenal syndrome in patients with alcoholic end stage liver disease listed for liver transplantation: role of transjugular intrahepatic portosystemic stent shunt. Panminerva Med. 2007;49:43–45. PMID: 17468733.
Testino G, Leone S, Ferro C, Borro P. Severe acute alcoholic hepatitis and hepatorenal syndrome: role of transjugular intrahepatic portosystemic stent shunt. J Med Life. 2012;5:203–205. PMID: 22802893.
Sibulesky L, Leca N, Blosser C, et al. Is MELD score failing patients with liver disease and hepatorenal syndrome? World J Hepatol. 2016;8:1155–1156. PMID: 27721921.
Testino G, Vignoli T, Patussi V, et al. Management of end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis: position paper of the Italian Society on Alcohol (SIA). Dig Liver Dis. 2020;52:21–32. https://doi.org/10.1016/j.dld.2019.09.017.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Testino, G. Transjugular Intrahepatic Porto Systemic Shunt for Hepatorenal Syndrome in Alcoholic Patients. Dig Dis Sci 66, 325–326 (2021). https://doi.org/10.1007/s10620-020-06243-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-020-06243-0